We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Anaspec Introduces Industry’s First Fluorimetric Kits

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

AnaSpec has announced the release of the industry first fluorimetric Factor Xa activity assays - The SensoLyte® 520 Factor Xa Assay Kit and the SensoLyte® Rh110 Factor Xa Assay Kit.

The SensoLyte® 520 Factor Xa Assay Kit employs a FRET (5-FAM/QXL™ 520) substrate and the SensoLyte® Rh110 Factor Xa Assay Kit, a substrate labeled with the fluorophore, Rh110.

Both substrates are fluorescent substrates emitting in the green range of 520 nm, with excitation at 490 nm.

The longer-wavelength spectra of 5-FAM and Rhodamine 110 provide greater sensitivity and less interference from other reaction components, making these kits ultra-sensitive.

The detection limit of the SensoLyte® 520 kit can reach as low as 7.8 ng/mL while the SensoLyte® Rho110 reaches as low as 0.31 ng/mL.

Key highlights for AnaSpec’s new SensoLyte® Factor Xa Assay Kits:

• Kits optimized to detect Factor Xa enzyme activity
• Fluorometric, long wavelength (Ex/Em=490/520 nm) read-out assays
• Minimal autofluorescence
• Kits provide ample reagents to perform 100 assays in a 96-well plate format
• Assays can be completed in one hour

Factor Xa (FXa) is a serine endopeptidase composed of two disulfide-linked subunits. FXa leads to blood clot formation by converting prothrombin to thrombin through the prothrombinase complex.

FXa is generated from zymogen Factor X via the intrinsic and extrinsic pathways and is the rate-limiting step in the propagation of thrombin generation.

In the presence of Ca2+ ions, FXa forms prothrombinase with factor Va on the phospholipid membrane of the activated platelets. FXa has emerged as an attractive target for drug discovery for thromboembolic diseases.